Testing PD-1 Inhibition With Neoadjuvant Anti-HER2 Therapy in Breast Cancer
At the American Society of Clinical Oncology (ASCO) annual meeting, researchers reported on a multicenter, phase II trial exploring the efficacy and safety of adding pembrolizumab (Keytruda) to the standard-of-care treatment of paclitaxel (Taxol), trastuzumab (Herceptin), and pertuzumab (Perjeta; THP) in chemotherapy-naive patients with invasive, HER2-positive breast cancer. In this exclusive MedPage Today video, Jin […]
PD-1 Inhibition in First-Line Prolongs Survival in Cervical Cancer
Updated findings of KEYNOTE-826, presented at the American Society of Clinical Oncology (ASCO) annual meeting, continued to demonstrate a significant survival benefit with the addition of pembrolizumab (Keytruda) to standard treatment for previously untreated recurrent or metastatic cervical cancer. In this exclusive MedPage Today video, Deanna Gerber, MD, of the NYU Long Island School of […]